Tag: orally disintegrating tablet market

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Orally Disintegrating Tablet Market Size And Revenue Outlook Through 2030

The orally disintegrating tablet market has demonstrated robust growth in recent years. It is forecast to rise from $16.2 billion in 2025 to $17.62 billion by 2026, achieving a compound annual growth rate (CAGR) of 8.8%. The historical period’s expansion was influenced by limited familiarity with orally disintegrating tablets, the dominance of traditional tablets, inadequate targeting for pediatric and geriatric populations, reliance on hospital pharmacy avenues, and a slow pace in adopting specialty drug formulations.

The orally disintegrating tablet market is projected to witness significant expansion in the coming years. Its valuation is expected to reach $24.43 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. The expansion during this forecast period can be attributed to technological breakthroughs in ODT formulation, an increasing patient preference for convenience and adherence, the development of online and retail pharmacy networks, a rising incidence of central nervous system and gastrointestinal disorders, and augmented research and development in antipsychotics and antiepileptics. Key trends anticipated in the forecast period include a growing demand for easy-to-swallow and patient-friendly dosage forms, an expansion in targeting pediatric and geriatric patient populations, growth in hospital and retail pharmacy distribution channels, an increased focus on rapid-onset therapeutics, and the rising adoption of specialty drug classes in ODT formulations.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=58407271&type=smp&name=Orally%20Disintegrating%20Tablet%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Orally Disintegrating Tablet Market Demand Drivers: What’s Powering Industry Growth?

The escalating occurrence of neurological disorders is set to fuel the growth of the orally disintegrating tablet market in the future. Neurological disorders are health conditions impacting the nervous system, encompassing the brain and peripheral nerves, which disrupt its normal functioning. The rise in these conditions is largely due to longer lifespans, as ailments like Alzheimer’s and Parkinson’s become more common with advancing age, leading to an overall increase in cases. Orally disintegrating tablets assist in managing neurological disorders by enabling simpler and quicker medication administration, especially for patients facing swallowing difficulties (dysphagia) or cognitive impairments, thereby improving treatment adherence, ensuring timely dosing, and enhancing the overall efficacy of therapy. For instance, in March 2023, the Alzheimer’s Association, a US-based nonprofit voluntary health organization, stated that in 2023, approximately 6.7 million Americans aged 65 and older are living with Alzheimer’s dementia, with projections indicating a surge to 13.8 million by 2060. Consequently, the increasing incidence of neurological disorders is propelling the expansion of the orally disintegrating tablet market.

Orally Disintegrating Tablet Market Segmentation: How Does The Market Break Down By Category?

The orally disintegrating tablet market covered in this report is segmented –

1) By Drug Class: Anti-Psychotics, Anti-Epileptics, Central Nervous System Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, Non-Steroidal Anti-Inflammatory Drugs, Anti-Allergy Drugs, Proton Pump Inhibitors, Other Drug Classes

2) By Disease Indication: Central Nervous System Disease, Gastrointestinal Disease, Cardiovascular System Disorders, Allergy, Other Disease Indications

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores

4) By Consumer Type: Pediatric, Adult, Geriatric

Subsegments:

1) By Anti-Psychotics: Atypical Anti-Psychotics, Typical Anti-Psychotics

2) By Anti-Epileptics: Sodium Channel Blockers, GABA Analogs, Other Anti-Epileptics

3) By Central Nervous System Stimulants: Amphetamine Derivatives, Methylphenidate, Other CNS Stimulants

4) By Anxiolytics: Benzodiazepines, Non-Benzodiazepine Anxiolytics

5) By Anti-Parkinsonian Drugs: Dopamine Agonists, MAO-B Inhibitors, Other Anti-Parkinsonian Drugs

6) By Anti-Hypertensives: Beta-Blockers, Calcium Channel Blockers, ACE Inhibitors, Other Anti-Hypertensives

7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Diclofenac, Other NSAIDs

8) By Anti-Allergy Drugs: Antihistamines, Corticosteroids

9) By Proton Pump Inhibitors: Omeprazole, Esomeprazole

10) By Other Drug Classes: Antiemetics, Antimigraine Drugs, Other Therapeutic Classes

Orally Disintegrating Tablet Market Innovation Trends: What Developments Are Reshaping The Industry?

Leading companies in the orally disintegrating tablet market are concentrating on innovating drug formulations, particularly patient-centric drug delivery systems, to bolster treatment adherence and improve patient outcomes. A patient-centric drug delivery system involves creating and administering medicines in a way that is easier and more comfortable for patients, consequently enhancing their treatment experience and compliance. For example, in May 2025, Viatris Inc., a US-based healthcare company, launched Gen-Clozapine orally disintegrating tablets (ODT) in Canada, introducing a novel treatment choice for treatment-resistant schizophrenia. It provides several distinctive attributes, positioning it as a significant contribution to the management of treatment-resistant schizophrenia in Canada. As the first clozapine orally disintegrating tablet (ODT) accessible in the country, it presents a patient-friendly alternative that quickly dissolves in the mouth without water, assisting individuals with swallowing difficulties or adherence issues. The product is offered in various strengths (12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg), allowing for flexible and precise dose titration based on a patient’s specific requirements. By incorporating clozapine, which is the only approved antipsychotic for treatment-resistant schizophrenia, the ODT formulation supports alignment with established treatment protocols.

Orally Disintegrating Tablet Market Competitive Overview And Top Companies

Major companies operating in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy’s Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions.

View The Full Orally Disintegrating Tablet Market Report:

https://thebusinessresearchcompany.com/report/orally-disintegrating-tablet-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Orally Disintegrating Tablet Market Regional Analysis: Which Region Leads By Revenue?

North America was the largest region in the orally disintegrating tablet market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orally disintegrating tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Orally Disintegrating Tablet Market Size Outlook: How Fast Will Revenue Grow Through 2030?

The market for orally disintegrating tablets has experienced robust expansion over the last few years. Valued at $16.2 billion in 2025, it is projected to reach $17.62 billion by 2026, reflecting a compound annual growth rate (CAGR) of 8.8%. Several factors drove growth during the historic period, including restricted knowledge about orally disintegrating tablets, the continued predominance of conventional tablets, insufficient focus on pediatric and geriatric populations, a strong dependency on hospital pharmacy channels, and a hesitant uptake of specialized drug formulations.

The market for orally disintegrating tablets is set to experience notable expansion over the coming years. Projections indicate it will reach $24.43 billion by 2030, with a compound annual growth rate (CAGR) of 8.5%. This anticipated growth during the forecast period is driven by several factors, including advances in ODT formulation technologies, a growing preference among patients for treatments that offer convenience and better compliance, the expansion of both online and retail pharmacy networks, the increasing prevalence of central nervous system and gastrointestinal disorders, and heightened research and development efforts focused on antipsychotic and antiepileptic medications. Key trends shaping this period encompass a rising demand for dosage forms that are easy to swallow and more patient-friendly, a broader targeting of pediatric and geriatric populations, the growth of hospital and retail pharmacy distribution channels, a heightened emphasis on therapies with rapid onset of action, and the greater incorporation of specialized drug classes into ODT formulations.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25857&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Orally Disintegrating Tablet Market Expansion Drivers: What Is Shaping Future Growth?

The growing prevalence of neurological conditions is anticipated to drive the expansion of the orally disintegrating tablet market in the coming years. These disorders are medical issues that impact the nervous system, encompassing the brain and peripheral nerves, thereby impairing its regular function. The rise in such cases is largely attributable to increased life expectancy, as age-related ailments like Alzheimer’s and Parkinson’s become more frequent, leading to a higher overall count of patients. Orally disintegrating tablets assist in managing neurological disorders by facilitating simpler and quicker drug delivery, which is particularly beneficial for individuals suffering from dysphagia or cognitive deficits, thereby boosting medication compliance, guaranteeing consistent dosing, and augmenting therapeutic outcomes. For example, in March 2023, data from the Alzheimer’s Association, a US-based nonprofit volunteer health organization, indicated that around 6.7 million Americans aged 65 and over were living with Alzheimer’s dementia in 2023, with forecasts pointing to a rise to 13.8 million by 2060. So, the mounting frequency of neurological disorders is accelerating progress in the orally disintegrating tablet market.

Orally Disintegrating Tablet Market Segment Breakdown: Which Categories Generate The Most Revenue?

The orally disintegrating tablet market covered in this report is segmented –

1) By Drug Class: Anti-Psychotics, Anti-Epileptics, Central Nervous System Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, Non-Steroidal Anti-Inflammatory Drugs, Anti-Allergy Drugs, Proton Pump Inhibitors, Other Drug Classes

2) By Disease Indication: Central Nervous System Disease, Gastrointestinal Disease, Cardiovascular System Disorders, Allergy, Other Disease Indications

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores

4) By Consumer Type: Pediatric, Adult, Geriatric

Subsegments:

1) By Anti-Psychotics: Atypical Anti-Psychotics, Typical Anti-Psychotics

2) By Anti-Epileptics: Sodium Channel Blockers, GABA Analogs, Other Anti-Epileptics

3) By Central Nervous System Stimulants: Amphetamine Derivatives, Methylphenidate, Other CNS Stimulants

4) By Anxiolytics: Benzodiazepines, Non-Benzodiazepine Anxiolytics

5) By Anti-Parkinsonian Drugs: Dopamine Agonists, MAO-B Inhibitors, Other Anti-Parkinsonian Drugs

6) By Anti-Hypertensives: Beta-Blockers, Calcium Channel Blockers, ACE Inhibitors, Other Anti-Hypertensives

7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Diclofenac, Other NSAIDs

8) By Anti-Allergy Drugs: Antihistamines, Corticosteroids

9) By Proton Pump Inhibitors: Omeprazole, Esomeprazole

10) By Other Drug Classes: Antiemetics, Antimigraine Drugs, Other Therapeutic Classes

Orally Disintegrating Tablet Market Strategic Trends: What Is Defining The Next Phase Of Growth?

Major players within the orally disintegrating tablet sector are prioritizing drug formulation breakthroughs, especially patient-focused delivery systems, to boost treatment compliance and achieve superior health results. A patient-centric delivery approach involves designing medications that are simpler and more convenient to take, thereby enhancing the overall therapeutic experience and adherence. As an example, in May 2025, the US healthcare company Viatris Inc. rolled out Gen-Clozapine orally disintegrating tablets (ODT) across Canada, delivering a fresh therapeutic choice for individuals battling treatment-resistant schizophrenia. This product brings several distinctive attributes that mark a notable advancement in managing this condition within the country. Being the first clozapine ODT available on the Canadian market, it offers a user-friendly option that dissolves rapidly in the mouth without requiring water, which benefits patients who face swallowing difficulties or struggle with consistent medication use. The tablets come in multiple strengths—12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg—enabling flexible and accurate dose adjustments tailored to each person’s requirements. By incorporating clozapine, the sole antipsychotic sanctioned for treatment-resistant schizophrenia, this ODT formulation ensures compatibility with well-established care protocols.

Orally Disintegrating Tablet Market Key Players And Strategic Industry Positioning

Major companies operating in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy’s Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions.

Access The Complete Orally Disintegrating Tablet Market Report:

https://www.thebusinessresearchcompany.com/report/orally-disintegrating-tablet-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Orally Disintegrating Tablet Market Regional Analysis And Leading Geography

North America was the largest region in the orally disintegrating tablet market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orally disintegrating tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Will Be The Estimated Market Size Of The Orally Disintegrating Tablet Market By 2030?

The orally disintegrating tablet market has seen substantial growth in recent years. It is projected to expand from $16.2 billion in 2025 to $17.62 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.8%. Historically, this growth can be linked to factors like limited awareness of orally disintegrating tablets, the prevalence of conventional tablets, insufficient targeting of pediatric and geriatric patients, dependence on hospital pharmacy channels, and the slow integration of specialty drug formulations.

The orally disintegrating tablet market is anticipated to experience substantial expansion over the coming years. It is projected to reach $24.43 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This growth during the forecast period can be attributed to several factors, including advancements in ODT formulation technology, a growing patient preference for convenient and compliant medication options, the expansion of both online and retail pharmacy networks, the increasing incidence of central nervous system (CNS) and gastrointestinal disorders, and augmented research and development efforts in anti-psychotics and anti-epileptics. Key developments expected during this period involve a rising demand for easily ingestible and patient-friendly dosage forms, increased targeting of pediatric and geriatric patient populations, the broadening of hospital and retail pharmacy distribution channels, a heightened focus on therapies with rapid onset, and the increasing incorporation of specialty drug classes into ODT formulations.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25857&type=smp

What Market Drivers Are Helping Shape The Orally Disintegrating Tablet Market Expansion?

The orally disintegrating tablet market is anticipated to expand due to the rising occurrence of neurological disorders. These conditions are defined as medical issues impacting the nervous system, encompassing the brain and peripheral nerves, thereby interfering with its normal operations. A primary reason for the increased prevalence of neurological disorders is extended lifespans, given that conditions like Alzheimer’s and Parkinson’s occur more frequently in older individuals, resulting in a general rise in diagnoses. Orally disintegrating tablets offer assistance in managing neurological disorders by facilitating quicker and simpler drug delivery, especially for individuals facing swallowing difficulties (dysphagia) or cognitive issues. They also boost patient compliance, guarantee appropriate dosing, and heighten therapeutic efficacy. As an illustration, in March 2023, data from the Alzheimer’s Association, a US-based nonprofit voluntary health organization, reported that approximately 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia in 2023, with forecasts suggesting this number will climb to 13.8 million by 2060. Consequently, the growing frequency of neurological disorders is a significant factor propelling the expansion of the orally disintegrating tablet market.

What Segment Categories Are Evaluated In The Orally Disintegrating Tablet Market Study?

The orally disintegrating tablet market covered in this report is segmented –

1) By Drug Class: Anti-Psychotics, Anti-Epileptics, Central Nervous System Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, Non-Steroidal Anti-Inflammatory Drugs, Anti-Allergy Drugs, Proton Pump Inhibitors, Other Drug Classes

2) By Disease Indication: Central Nervous System Disease, Gastrointestinal Disease, Cardiovascular System Disorders, Allergy, Other Disease Indications

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores

4) By Consumer Type: Pediatric, Adult, Geriatric

Subsegments:

1) By Anti-Psychotics: Atypical Anti-Psychotics, Typical Anti-Psychotics

2) By Anti-Epileptics: Sodium Channel Blockers, GABA Analogs, Other Anti-Epileptics

3) By Central Nervous System Stimulants: Amphetamine Derivatives, Methylphenidate, Other CNS Stimulants

4) By Anxiolytics: Benzodiazepines, Non-Benzodiazepine Anxiolytics

5) By Anti-Parkinsonian Drugs: Dopamine Agonists, MAO-B Inhibitors, Other Anti-Parkinsonian Drugs

6) By Anti-Hypertensives: Beta-Blockers, Calcium Channel Blockers, ACE Inhibitors, Other Anti-Hypertensives

7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Diclofenac, Other NSAIDs

8) By Anti-Allergy Drugs: Antihistamines, Corticosteroids

9) By Proton Pump Inhibitors: Omeprazole, Esomeprazole

10) By Other Drug Classes: Antiemetics, Antimigraine Drugs, Other Therapeutic Classes

What Trends Are Affecting The Orally Disintegrating Tablet Market Dynamics?

Companies operating within the orally disintegrating tablet market are prioritizing advancements in drug formulation, specifically patient-centric drug delivery systems, to enhance treatment adherence and improve patient outcomes. A patient-centric drug delivery system refers to a method of designing and administering medicines to make them easier and more comfortable for patients to take, thereby improving their treatment experience and adherence. For instance, in May 2025, Viatris Inc., a US-based healthcare company, introduced Gen-Clozapine orally disintegrating tablets (ODT) in Canada, offering a new treatment option for treatment-resistant schizophrenia. This product provides several unique features, making it a significant addition to the management of treatment-resistant schizophrenia in Canada. As the first clozapine orally disintegrating tablet (ODT) available in the country, it presents a patient-friendly option that disintegrates quickly in the mouth without water, assisting those with difficulty swallowing or adherence challenges. The product is available in multiple strengths (12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg), enabling flexible and precise dose titration based on individual patient needs. By utilizing clozapine, the only approved antipsychotic for treatment-resistant schizophrenia, the ODT formulation supports alignment with established treatment protocols.

Which Companies Form The Competitive Landscape Of The Orally Disintegrating Tablet Market?

Major companies operating in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy’s Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions.

Access The Complete Orally Disintegrating Tablet Market Report:

https://www.thebusinessresearchcompany.com/report/orally-disintegrating-tablet-global-market-report

Which Area Represents The Largest Portion Of The Orally Disintegrating Tablet Market?

North America was the largest region in the orally disintegrating tablet market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orally disintegrating tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Orally Disintegrating Tablet Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=25857&type=smp

Browse Through More Reports Similar to the Global Orally Disintegrating Tablet Market 2026, By The Business Research Company

Tablets Market Report 2026

https://www.thebusinessresearchcompany.com/report/tablets-global-market-report

Effervescent Tablet Market Report 2026

https://www.thebusinessresearchcompany.com/report/effervescent-tablet-global-market-report

Oral Solid Dosage Pharmaceutical Formulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-solid-dosage-pharmaceutical-formulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Orally Disintegrating Tablet Market In 2026, And How Will Its Value Evolve By 2030?

The orally disintegrating tablet market size has experienced substantial growth in recent years. It is projected to increase from $16.2 billion in 2025 to $17.62 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.8%. Historically, this growth can be attributed to factors such as limited awareness of orally disintegrating tablets, the dominance of conventional tablets, insufficient targeting of pediatric and geriatric populations, heavy reliance on hospital pharmacy channels, and the gradual adoption of specialty drug formulations.

The orally disintegrating tablet market is projected to experience substantial expansion in the coming years, with its valuation anticipated to reach $24.43 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.5%. This expansion during the forecast period is primarily driven by various factors, including advancements in orally disintegrating tablet (ODT) formulation technology, a growing patient preference for convenient and compliant medication options, the expansion of online and retail pharmacy networks, an increasing incidence of CNS and gastrointestinal disorders, and enhanced research and development efforts in anti-psychotics and anti-epileptics. Key developments shaping the market outlook encompass a heightened demand for user-friendly and easy-to-swallow dosage forms, a broadened focus on pediatric and geriatric patient segments, the expansion of distribution channels through hospitals and retail pharmacies, an increased emphasis on therapeutics with rapid onset of action, and the growing incorporation of specialty drug classes into orally disintegrating tablet formulations.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25857&type=smp

Which Major Drivers Are Influencing The Expansion Of The Orally Disintegrating Tablet Market?

The increasing prevalence of neurological disorders is anticipated to stimulate the future growth of the orally disintegrating tablet market. Neurological disorders are medical conditions that impact the nervous system, encompassing the brain and peripheral nerves, thereby disrupting its normal functioning. The rise in these disorders primarily results from increased human longevity, as conditions such as Alzheimer’s and Parkinson’s become more prevalent with age, leading to an overall increase in cases. Orally disintegrating tablets offer advantages in treating neurological disorders by enabling easier and faster medication administration, especially for patients experiencing difficulty swallowing (dysphagia) or cognitive impairments. This approach enhances treatment adherence, ensures timely dosing, and boosts the overall effectiveness of therapy. For instance, in March 2023, the Alzheimer’s Association, a US-based nonprofit voluntary health organization, reported that in 2023, about 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia, with projections indicating an increase to 13.8 million by 2060. Therefore, the expanding incidence of neurological disorders is a significant factor driving the growth of the orally disintegrating tablet market.

What Are The Key Segment Divisions In The Orally Disintegrating Tablet Market Segment Structure?

The orally disintegrating tablet market covered in this report is segmented –

1) By Drug Class: Anti-Psychotics, Anti-Epileptics, Central Nervous System Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, Non-Steroidal Anti-Inflammatory Drugs, Anti-Allergy Drugs, Proton Pump Inhibitors, Other Drug Classes

2) By Disease Indication: Central Nervous System Disease, Gastrointestinal Disease, Cardiovascular System Disorders, Allergy, Other Disease Indications

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores

4) By Consumer Type: Pediatric, Adult, Geriatric

Subsegments:

1) By Anti-Psychotics: Atypical Anti-Psychotics, Typical Anti-Psychotics

2) By Anti-Epileptics: Sodium Channel Blockers, GABA Analogs, Other Anti-Epileptics

3) By Central Nervous System Stimulants: Amphetamine Derivatives, Methylphenidate, Other CNS Stimulants

4) By Anxiolytics: Benzodiazepines, Non-Benzodiazepine Anxiolytics

5) By Anti-Parkinsonian Drugs: Dopamine Agonists, MAO-B Inhibitors, Other Anti-Parkinsonian Drugs

6) By Anti-Hypertensives: Beta-Blockers, Calcium Channel Blockers, ACE Inhibitors, Other Anti-Hypertensives

7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Diclofenac, Other NSAIDs

8) By Anti-Allergy Drugs: Antihistamines, Corticosteroids

9) By Proton Pump Inhibitors: Omeprazole, Esomeprazole

10) By Other Drug Classes: Antiemetics, Antimigraine Drugs, Other Therapeutic Classes

Which Trends Are Contributing To Changes In The Orally Disintegrating Tablet Market?

Companies operating within the orally disintegrating tablet market are prioritizing advancements in drug formulation, particularly through patient-centric drug delivery systems, to enhance treatment adherence and improve patient outcomes. A patient-centric drug delivery system involves designing and delivering medicines in a way that makes them more convenient and comfortable for patients to take, thereby enhancing their treatment experience and compliance. For example, in May 2025, Viatris Inc., a US-based healthcare company, launched Gen-Clozapine orally disintegrating tablets (ODT) in Canada, offering a new treatment option for treatment-resistant schizophrenia. This product features several distinct characteristics, establishing it as a significant addition to the management of treatment-resistant schizophrenia in Canada. Being the first clozapine orally disintegrating tablet (ODT) available in the country, it presents a patient-friendly alternative that rapidly dissolves in the mouth without water, beneficial for those with swallowing difficulties or adherence issues. The product comes in multiple strengths—12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg—allowing for flexible and precise dose adjustments based on individual patient needs. By utilizing clozapine, the only approved antipsychotic for treatment-resistant schizophrenia, the ODT formulation aligns with established treatment protocols.

Which Organizations Are Engaged In The Orally Disintegrating Tablet Market?

Major companies operating in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy’s Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions.

Get The Full Orally Disintegrating Tablet Market Report:

https://www.thebusinessresearchcompany.com/report/orally-disintegrating-tablet-global-market-report

Which Region Is The Largest In The Orally Disintegrating Tablet Market?

North America was the largest region in the orally disintegrating tablet market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orally disintegrating tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Orally Disintegrating Tablet Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/orally-disintegrating-tablet-global-market-report

Browse Through More Reports Similar to the Global Orally Disintegrating Tablet Market 2026, By The Business Research Company

Tablets Market Report 2026

https://www.thebusinessresearchcompany.com/report/tablets-global-market-report

Effervescent Tablet Market Report 2026

https://www.thebusinessresearchcompany.com/report/effervescent-tablet-global-market-report

Oral Solid Dosage Pharmaceutical Formulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-solid-dosage-pharmaceutical-formulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Orally Disintegrating Tablet Market At The End Of The 2026–2030 Forecast Period?

The orally disintegrating tablet market size has experienced strong growth in recent years. Its value is anticipated to rise from $16.2 billion in 2025 to $17.62 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.8%. During the historical period, this growth was impacted by factors including limited awareness of orally disintegrating tablets, the dominance of conventional tablets, low targeting of pediatric and geriatric populations, reliance on hospital pharmacy channels, and the slow adoption of specialty drug formulations.

The orally disintegrating tablet market size is projected to experience robust growth in the upcoming years. It is forecasted to reach $24.43 billion in 2030, achieving a compound annual growth rate (CAGR) of 8.5%. The expansion during the forecast period is attributable to technological advancements in ODT formulation, a rising patient inclination for convenience and adherence, the proliferation of online and retail pharmacy networks, an increasing incidence of CNS and gastrointestinal disorders, and expanding research and development in anti-psychotics and anti-epileptics. Key trends observed in the forecast period encompass a surging demand for easily ingestible and patient-friendly dosage forms, an broadened focus on pediatric and geriatric patient demographics, the development of hospital and retail pharmacy distribution channels, an increased emphasis on rapid-onset therapeutics, and the growing adoption of specialty drug classes in ODT formulations.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25857&type=smp

Which Market Drivers Are Supporting The Expansion Of The Orally Disintegrating Tablet Market?

The rising occurrence of neurological disorders is anticipated to stimulate the expansion of the orally disintegrating tablet market. These conditions are medical issues impacting the nervous system, including the brain and peripheral nerves, thereby disrupting its regular functions. The escalating prevalence of neurological disorders is primarily linked to increased longevity, as illnesses like Alzheimer’s and Parkinson’s become more prevalent with advancing age, contributing to a general rise in cases. Orally disintegrating tablets assist in managing neurological disorders by facilitating simpler and quicker medication delivery, especially for individuals facing difficulties with swallowing (dysphagia) or cognitive impairments, leading to better treatment compliance, timely dosing, and enhanced therapeutic efficacy. For example, in March 2023, data from the Alzheimer’s Association, a US-based nonprofit voluntary health organization, indicated that in 2023, approximately 6.7 million Americans aged 65 and older are currently living with Alzheimer’s dementia, with forecasts suggesting this number will climb to 13.8 million by 2060. Consequently, the growing incidence of neurological disorders is a key factor boosting the orally disintegrating tablet market.

What Segment Types Make Up The Orally Disintegrating Tablet Market?

The orally disintegrating tablet market covered in this report is segmented –

1) By Drug Class: Anti-Psychotics, Anti-Epileptics, Central Nervous System Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, Non-Steroidal Anti-Inflammatory Drugs, Anti-Allergy Drugs, Proton Pump Inhibitors, Other Drug Classes

2) By Disease Indication: Central Nervous System Disease, Gastrointestinal Disease, Cardiovascular System Disorders, Allergy, Other Disease Indications

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores

4) By Consumer Type: Pediatric, Adult, Geriatric

Subsegments:

1) By Anti-Psychotics: Atypical Anti-Psychotics, Typical Anti-Psychotics

2) By Anti-Epileptics: Sodium Channel Blockers, GABA Analogs, Other Anti-Epileptics

3) By Central Nervous System Stimulants: Amphetamine Derivatives, Methylphenidate, Other CNS Stimulants

4) By Anxiolytics: Benzodiazepines, Non-Benzodiazepine Anxiolytics

5) By Anti-Parkinsonian Drugs: Dopamine Agonists, MAO-B Inhibitors, Other Anti-Parkinsonian Drugs

6) By Anti-Hypertensives: Beta-Blockers, Calcium Channel Blockers, ACE Inhibitors, Other Anti-Hypertensives

7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Diclofenac, Other NSAIDs

8) By Anti-Allergy Drugs: Antihistamines, Corticosteroids

9) By Proton Pump Inhibitors: Omeprazole, Esomeprazole

10) By Other Drug Classes: Antiemetics, Antimigraine Drugs, Other Therapeutic Classes

Which Market Trends Are Creating New Opportunities In The Orally Disintegrating Tablet Market?

Companies with significant presence in the orally disintegrating tablet market are prioritizing novel drug formulation techniques, including patient-centric drug delivery systems, to boost patient compliance with treatments and achieve better health results. This type of system focuses on creating and providing medicines that are simpler and more pleasant for patients to consume, thereby enhancing their overall experience and consistency in taking medication. For example, Viatris Inc., a US-based healthcare company, introduced Gen-Clozapine orally disintegrating tablets (ODT) in Canada in May 2025, presenting a new therapeutic choice for individuals with treatment-resistant schizophrenia. The product boasts several distinct features, marking it as a valuable advancement in the management of treatment-resistant schizophrenia within Canada. As the initial clozapine orally disintegrating tablet (ODT) to be released in the nation, it offers an accessible format that rapidly dissolves in the mouth without requiring water, which assists patients who struggle with swallowing or maintaining adherence. Available in various strengths (12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg), the medication enables adaptable and precise dose adjustments according to specific patient requirements. By utilizing clozapine, recognized as the sole approved antipsychotic for treatment-resistant schizophrenia, the ODT formulation ensures compliance with established treatment guidelines.

Who Are The Key Players Driving Competition In The Orally Disintegrating Tablet Market?

Major companies operating in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy’s Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions.

Read the full orally disintegrating tablet market report here:

https://www.thebusinessresearchcompany.com/report/orally-disintegrating-tablet-global-market-report

How Is The Orally Disintegrating Tablet Market Distributed Across Key Geographic Regions?

North America was the largest region in the orally disintegrating tablet market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orally disintegrating tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Orally Disintegrating Tablet Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25857&type=smp

Browse Through More Reports Similar to the Global Orally Disintegrating Tablet Market 2026, By The Business Research Company

Tablets Market Report 2026

https://www.thebusinessresearchcompany.com/report/tablets-global-market-report

Effervescent Tablet Market Report 2026

https://www.thebusinessresearchcompany.com/report/effervescent-tablet-global-market-report

Oral Solid Dosage Pharmaceutical Formulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-solid-dosage-pharmaceutical-formulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the orally disintegrating tablet market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Orally Disintegrating Tablet Market be in 2030 compared with 2026?

The orally disintegrating tablet market size has shown strong growth in recent years. It is forecast to increase from $16.2 billion in 2025 to $17.62 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.8%. Historically, the expansion observed in this market can be linked to aspects like limited awareness of orally disintegrating tablets, the dominance of conventional tablets, minimal targeting of pediatric and geriatric demographics, reliance on hospital pharmacy channels, and the slow adoption of specialty drug formulations.

The orally disintegrating tablet market is projected to experience substantial expansion over the coming years. This market is set to reach $24.43 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. Factors contributing to this growth during the forecast period include innovations in ODT formulation technology, a growing patient preference for ease of use and adherence, the expansion of online and retail pharmacy channels, an increase in the occurrence of CNS and gastrointestinal disorders, and enhanced research and development in anti-psychotics and anti-epileptics. Key trends anticipated in this period encompass a growing demand for dosage forms that are simple to swallow and patient-centric, an increase in targeting pediatric and geriatric patient populations, the enlargement of hospital and retail pharmacy distribution networks, a heightened emphasis on fast-acting therapeutics, and the increasing incorporation of specialty drug categories within ODT formulations.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25857&type=smp

What Drivers Are Guiding Growth Patterns In The Orally Disintegrating Tablet Market?

The increasing prevalence of neurological disorders is anticipated to drive the expansion of the orally disintegrating tablet market moving forward. Neurological disorders are health conditions that impact the nervous system, encompassing the brain and peripheral nerves, and interfere with its normal functioning. The growing number of neurological disorders is primarily attributed to people living longer, as age-related conditions such as Alzheimer’s and Parkinson’s become more common, resulting in an overall surge in cases. Orally disintegrating tablets assist in managing neurological disorders by enabling easier and faster medication administration, particularly beneficial for patients with dysphagia (difficulty swallowing) or cognitive impairments, thereby improving treatment adherence, ensuring punctual dosing, and enhancing the overall effectiveness of therapy. For example, in March 2023, the Alzheimer’s Association, a US-based nonprofit voluntary health organization, stated that in 2023, roughly 6.7 million Americans aged 65 and older are living with Alzheimer’s dementia, with projections suggesting this figure will rise to 13.8 million by 2060. Hence, the rising incidence of neurological disorders is fueling the growth of the orally disintegrating tablet market.

Which Segments Are Driving Activity In The Orally Disintegrating Tablet Market?

The orally disintegrating tablet market covered in this report is segmented –

1) By Drug Class: Anti-Psychotics, Anti-Epileptics, Central Nervous System Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, Non-Steroidal Anti-Inflammatory Drugs, Anti-Allergy Drugs, Proton Pump Inhibitors, Other Drug Classes

2) By Disease Indication: Central Nervous System Disease, Gastrointestinal Disease, Cardiovascular System Disorders, Allergy, Other Disease Indications

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores

4) By Consumer Type: Pediatric, Adult, Geriatric

Subsegments:

1) By Anti-Psychotics: Atypical Anti-Psychotics, Typical Anti-Psychotics

2) By Anti-Epileptics: Sodium Channel Blockers, GABA Analogs, Other Anti-Epileptics

3) By Central Nervous System Stimulants: Amphetamine Derivatives, Methylphenidate, Other CNS Stimulants

4) By Anxiolytics: Benzodiazepines, Non-Benzodiazepine Anxiolytics

5) By Anti-Parkinsonian Drugs: Dopamine Agonists, MAO-B Inhibitors, Other Anti-Parkinsonian Drugs

6) By Anti-Hypertensives: Beta-Blockers, Calcium Channel Blockers, ACE Inhibitors, Other Anti-Hypertensives

7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Diclofenac, Other NSAIDs

8) By Anti-Allergy Drugs: Antihistamines, Corticosteroids

9) By Proton Pump Inhibitors: Omeprazole, Esomeprazole

10) By Other Drug Classes: Antiemetics, Antimigraine Drugs, Other Therapeutic Classes

Which Trends Are Shaping Activity Within The Orally Disintegrating Tablet Market?

Major companies in the orally disintegrating tablet market are concentrating on innovations in drug formulation, such as patient-centric drug delivery systems, to improve treatment adherence and patient outcomes. A patient-centric drug delivery system refers to designing and providing medicines in a way that makes them easier and more comfortable for patients to take, enhancing their treatment experience and compliance. For instance, in May 2025, Viatris Inc., a US-based healthcare company, launched Gen-Clozapine orally disintegrating tablets (ODT) in Canada, offering a new treatment option for treatment-resistant schizophrenia. This product features several unique aspects, making it a significant enhancement for managing treatment-resistant schizophrenia in Canada. As the first clozapine orally disintegrating tablet (ODT) available in the country, it provides a patient-friendly alternative that rapidly disintegrates in the mouth without water, assisting those with swallowing difficulties or adherence issues. The product is offered in multiple strengths (12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg), allowing for flexible and precise dose titration based on individual patient needs. By incorporating clozapine, the only approved antipsychotic for treatment-resistant schizophrenia, the ODT formulation aligns with established treatment protocols.

Which Major Industry Participants Are Leading The Orally Disintegrating Tablet Market Growth?

Major companies operating in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy’s Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/orally-disintegrating-tablet-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Orally Disintegrating Tablet Market?

North America was the largest region in the orally disintegrating tablet market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orally disintegrating tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Orally Disintegrating Tablet Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25857&type=smp

Browse Through More Reports Similar to the Global Orally Disintegrating Tablet Market 2026, By The Business Research Company

Tablets Market Report 2026

https://www.thebusinessresearchcompany.com/report/tablets-global-market-report

Effervescent Tablet Market Report 2026

https://www.thebusinessresearchcompany.com/report/effervescent-tablet-global-market-report

Oral Solid Dosage Pharmaceutical Formulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-solid-dosage-pharmaceutical-formulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the orally disintegrating tablet market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Orally Disintegrating Tablet Market be in 2030 compared with 2026?

The orally disintegrating tablet market size has shown strong growth in recent years. It is forecast to increase from $16.2 billion in 2025 to $17.62 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.8%. Historically, the expansion observed in this market can be linked to aspects like limited awareness of orally disintegrating tablets, the dominance of conventional tablets, minimal targeting of pediatric and geriatric demographics, reliance on hospital pharmacy channels, and the slow adoption of specialty drug formulations.

The orally disintegrating tablet market is projected to experience substantial expansion over the coming years. This market is set to reach $24.43 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. Factors contributing to this growth during the forecast period include innovations in ODT formulation technology, a growing patient preference for ease of use and adherence, the expansion of online and retail pharmacy channels, an increase in the occurrence of CNS and gastrointestinal disorders, and enhanced research and development in anti-psychotics and anti-epileptics. Key trends anticipated in this period encompass a growing demand for dosage forms that are simple to swallow and patient-centric, an increase in targeting pediatric and geriatric patient populations, the enlargement of hospital and retail pharmacy distribution networks, a heightened emphasis on fast-acting therapeutics, and the increasing incorporation of specialty drug categories within ODT formulations.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25857&type=smp

What Drivers Are Guiding Growth Patterns In The Orally Disintegrating Tablet Market?

The increasing prevalence of neurological disorders is anticipated to drive the expansion of the orally disintegrating tablet market moving forward. Neurological disorders are health conditions that impact the nervous system, encompassing the brain and peripheral nerves, and interfere with its normal functioning. The growing number of neurological disorders is primarily attributed to people living longer, as age-related conditions such as Alzheimer’s and Parkinson’s become more common, resulting in an overall surge in cases. Orally disintegrating tablets assist in managing neurological disorders by enabling easier and faster medication administration, particularly beneficial for patients with dysphagia (difficulty swallowing) or cognitive impairments, thereby improving treatment adherence, ensuring punctual dosing, and enhancing the overall effectiveness of therapy. For example, in March 2023, the Alzheimer’s Association, a US-based nonprofit voluntary health organization, stated that in 2023, roughly 6.7 million Americans aged 65 and older are living with Alzheimer’s dementia, with projections suggesting this figure will rise to 13.8 million by 2060. Hence, the rising incidence of neurological disorders is fueling the growth of the orally disintegrating tablet market.

Which Segments Are Driving Activity In The Orally Disintegrating Tablet Market?

The orally disintegrating tablet market covered in this report is segmented –

1) By Drug Class: Anti-Psychotics, Anti-Epileptics, Central Nervous System Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, Non-Steroidal Anti-Inflammatory Drugs, Anti-Allergy Drugs, Proton Pump Inhibitors, Other Drug Classes

2) By Disease Indication: Central Nervous System Disease, Gastrointestinal Disease, Cardiovascular System Disorders, Allergy, Other Disease Indications

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores

4) By Consumer Type: Pediatric, Adult, Geriatric

Subsegments:

1) By Anti-Psychotics: Atypical Anti-Psychotics, Typical Anti-Psychotics

2) By Anti-Epileptics: Sodium Channel Blockers, GABA Analogs, Other Anti-Epileptics

3) By Central Nervous System Stimulants: Amphetamine Derivatives, Methylphenidate, Other CNS Stimulants

4) By Anxiolytics: Benzodiazepines, Non-Benzodiazepine Anxiolytics

5) By Anti-Parkinsonian Drugs: Dopamine Agonists, MAO-B Inhibitors, Other Anti-Parkinsonian Drugs

6) By Anti-Hypertensives: Beta-Blockers, Calcium Channel Blockers, ACE Inhibitors, Other Anti-Hypertensives

7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Diclofenac, Other NSAIDs

8) By Anti-Allergy Drugs: Antihistamines, Corticosteroids

9) By Proton Pump Inhibitors: Omeprazole, Esomeprazole

10) By Other Drug Classes: Antiemetics, Antimigraine Drugs, Other Therapeutic Classes

Which Trends Are Shaping Activity Within The Orally Disintegrating Tablet Market?

Major companies in the orally disintegrating tablet market are concentrating on innovations in drug formulation, such as patient-centric drug delivery systems, to improve treatment adherence and patient outcomes. A patient-centric drug delivery system refers to designing and providing medicines in a way that makes them easier and more comfortable for patients to take, enhancing their treatment experience and compliance. For instance, in May 2025, Viatris Inc., a US-based healthcare company, launched Gen-Clozapine orally disintegrating tablets (ODT) in Canada, offering a new treatment option for treatment-resistant schizophrenia. This product features several unique aspects, making it a significant enhancement for managing treatment-resistant schizophrenia in Canada. As the first clozapine orally disintegrating tablet (ODT) available in the country, it provides a patient-friendly alternative that rapidly disintegrates in the mouth without water, assisting those with swallowing difficulties or adherence issues. The product is offered in multiple strengths (12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg), allowing for flexible and precise dose titration based on individual patient needs. By incorporating clozapine, the only approved antipsychotic for treatment-resistant schizophrenia, the ODT formulation aligns with established treatment protocols.

Which Major Industry Participants Are Leading The Orally Disintegrating Tablet Market Growth?

Major companies operating in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy’s Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/orally-disintegrating-tablet-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Orally Disintegrating Tablet Market?

North America was the largest region in the orally disintegrating tablet market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orally disintegrating tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Orally Disintegrating Tablet Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25857&type=smp

Browse Through More Reports Similar to the Global Orally Disintegrating Tablet Market 2026, By The Business Research Company

Tablets Market Report 2026

https://www.thebusinessresearchcompany.com/report/tablets-global-market-report

Effervescent Tablet Market Report 2026

https://www.thebusinessresearchcompany.com/report/effervescent-tablet-global-market-report

Oral Solid Dosage Pharmaceutical Formulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-solid-dosage-pharmaceutical-formulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Orally Disintegrating Tablet Market Size During 2025–2029?

The orally disintegrating tablet market size has seen significant growth over recent years. This market is expected to expand from $14.88 billion in 2024 to $16.20 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.8%. Historically, this expansion has been driven by factors such as the increasing pediatric and geriatric demographics, the rising prevalence of central nervous system disorders, the heightened demand for convenient methods of drug delivery, the growing number of dysphagia cases, and the increased adoption of outpatient care services.

The market for orally disintegrating tablets is projected to experience robust expansion over the coming years. This market is set to reach $22.53 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.6%. Several factors are expected to fuel this growth during the forecast period, including the rising incidence of chronic illnesses, a growing inclination towards self-medication, the broader adoption of telemedicine and e-pharmacies, an enhanced emphasis on personalized medicine, increased consumer demand for vegan and allergen-free formulations, and a steadily increasing elderly demographic. Key trends anticipated in the forecast period encompass the creation of multi-drug orally disintegrating tablets, their incorporation into digital health platforms, breakthroughs in packaging design to enhance stability and portability, the evolution of taste-masking technologies, and significant strides in formulation technology.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25857&type=smp

What Are The Top Growth Drivers Impacting The Orally Disintegrating Tablet Market Outlook?

The rising occurrence of neurological conditions is anticipated to fuel the expansion of the orally disintegrating tablet market in the future. Neurological disorders are health issues that impact the nervous system, encompassing the brain and peripheral nerves, thereby hindering its regular operation. The growing prevalence of these disorders is primarily attributed to extended lifespans, given that ailments such as Alzheimer’s and Parkinson’s tend to occur more frequently as individuals age, resulting in a general rise in diagnoses. Orally disintegrating tablets assist in managing neurological disorders by facilitating simpler and quicker drug delivery, especially for individuals facing swallowing difficulties (dysphagia) or cognitive challenges. This boosts treatment compliance, guarantees punctual dosages, and improves the overall efficacy of therapy. For instance, in March 2023, according to the Alzheimer’s Association, a US-based nonprofit voluntary health organization, approximately 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia in 2023, with projections indicating an increase to 13.8 million by 2060. Consequently, the escalating incidence of neurological disorders is driving the growth of the orally disintegrating tablet market.

How Is The Orally Disintegrating Tablet Market Segmented?

The orally disintegrating tablet market covered in this report is segmented –

1) By Drug Class: Anti-Psychotics, Anti-Epileptics, Central Nervous System Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, Non-Steroidal Anti-Inflammatory Drugs, Anti-Allergy Drugs, Proton Pump Inhibitors, Other Drug Classes

2) By Disease Indication: Central Nervous System Disease, Gastrointestinal Disease, Cardiovascular System Disorders, Allergy, Other Disease Indications

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores

4) By Consumer Type: Pediatric, Adult, Geriatric

Subsegments:

1) By Anti-Psychotics: Atypical Anti-Psychotics, Typical Anti-Psychotics

2) By Anti-Epileptics: Sodium Channel Blockers, GABA Analogs, Other Anti-Epileptics

3) By Central Nervous System Stimulants: Amphetamine Derivatives, Methylphenidate, Other CNS Stimulants

4) By Anxiolytics: Benzodiazepines, Non-Benzodiazepine Anxiolytics

5) By Anti-Parkinsonian Drugs: Dopamine Agonists, MAO-B Inhibitors, Other Anti-Parkinsonian Drugs

6) By Anti-Hypertensives: Beta-Blockers, Calcium Channel Blockers, ACE Inhibitors, Other Anti-Hypertensives

7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Diclofenac, Other NSAIDs

8) By Anti-Allergy Drugs: Antihistamines, Corticosteroids

9) By Proton Pump Inhibitors: Omeprazole, Esomeprazole, Other PPIs

10) By Other Drug Classes: Antiemetics, Antimigraine Drugs, Other Therapeutic Classes

What Are The Major Trends Driving The Growth Of The Orally Disintegrating Tablet Market?

Leading companies in the orally disintegrating tablet market are concentrating on innovations in drug creation, such as patient-centric drug delivery systems, to improve treatment adherence and patient outcomes. A patient-centric drug delivery system describes a method of designing and delivering medications to make them simpler and more comfortable for patients to consume, thereby enhancing their treatment experience and compliance. For example, in May 2025, Viatris Inc., a US-based healthcare company, introduced Gen-Clozapine orally disintegrating tablets (ODT) in Canada, presenting a new therapeutic choice for treatment-resistant schizophrenia. It provides several distinctive characteristics, making it a notable contribution to the management of treatment-resistant schizophrenia in Canada. As the initial clozapine orally disintegrating tablet (ODT) available in the nation, it offers a patient-friendly alternative that dissolves swiftly in the mouth without water, assisting those who struggle with swallowing or adherence difficulties. The product is offered in multiple potencies (12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg), enabling adaptable and accurate dose adjustments according to individual patient requirements. By incorporating clozapine, the only approved antipsychotic for treatment-resistant schizophrenia, this ODT formulation supports conformity with established treatment guidelines.

Which Leading Companies Dominate The Orally Disintegrating Tablet Market Share?

Major companies operating in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy’s Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions, KalVista Pharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/orally-disintegrating-tablet-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Orally Disintegrating Tablet Market?

North America was the largest region in the orally disintegrating tablet market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orally disintegrating tablet market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Orally Disintegrating Tablet Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25857&type=smp

Browse Through More Reports Similar to the Global Orally Disintegrating Tablet Market 2025, By The Business Research Company

Tablets Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/tablets-global-market-report

Effervescent Tablet Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/effervescent-tablet-global-market-report

Oral Solid Dosage Pharmaceutical Formulation Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/oral-solid-dosage-pharmaceutical-formulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

#What Is The Current Size And Growth Outlook For The Orally Disintegrating Tablet Market?#_x000D_

The market for orally disintegrating tablets has experienced significant growth over recent years, expanding from a worth of $14.88 billion in 2024 to an estimated $16.20 billion in 2025 with a Compound Annual Growth Rate (CAGR) of 8.8%. This historical period growth can be linked to several factors including the increase in pediatric and elderly populations, a rising number of central nervous system disorders, escalating demand for easy drug delivery methods, an increase in cases of dysphagia, and the surge in utilization of outpatient care._x000D_

_x000D_

The market size for orally disintegrating tablets is projected to witness significant expansion in the upcoming years, reaching a value of $22.53 billion by 2029 with a CAGR of 8.6%. Various factors contribute to this escalation during the expected period including the growing prevalence of chronic illnesses, the broadening trend for self-care, a surge in the use of telemedicine and e-pharmacies, an increased emphasis on personalized medicine, a spike in demand for vegan and allergen-free drugs, and a rising elderly population. Notable developing trends during this forecast period encompass the production of multi-drug orally disintegrating tablets, incorporation with digital health platforms, advancements in packaging for enhanced stability and portability, taste-altering technologies, and progress in formulation technology._x000D_

_x000D_

#Get A Free Sample Of The Report:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=25857&type=smp_x000D_

_x000D_

#What Core Drivers Are Expected To Influence The Orally Disintegrating Tablet Market?#_x000D_

The surge in neurological disorders is predicted to fuel the expansion of the orally disintegrating tablet market. Neurological disorders are health issues impacting the nervous system, including the brain and peripheral nerves, disrupting the standard functioning of the system. The growing prevalence of these disorders is primarily attributed to increased longevity as diseases like Alzheimer’s and Parkinson’s become more prevalent with aging, resulting in an overall case surge. Orally disintegrating tablets are beneficial in treating neurological disorders by enabling easier and quicker drug administration, especially for patients struggling with swallowing disorders (dysphagia) or cognitive impairments. They enhance adherence to treatment, ensure proper timing of dosage, and boost overall therapy effectiveness. For example, the Alzheimer’s Association, a nonprofit voluntary health organization based in the US, reported in March 2023 that in the same year, around 6.7 million Americans aged over 65 are living with Alzheimer’s dementia. Projections highlight a surge to 13.8 million by 2060. Therefore, the growing occurrence of neurological disorders is propelling the expansion of the orally disintegrating tablet market._x000D_

_x000D_

#Which Segmentation Categories Are Highlighted In The Orally Disintegrating Tablet Market Analysis?#_x000D_

The orally disintegrating tablet market covered in this report is segmented – _x000D_

_x000D_

1) By Drug Class: Anti-Psychotics, Anti-Epileptics, Central Nervous System Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, Non-Steroidal Anti-Inflammatory Drugs, Anti-Allergy Drugs, Proton Pump Inhibitors, Other Drug Classes _x000D_

2) By Disease Indication: Central Nervous System Disease, Gastrointestinal Disease, Cardiovascular System Disorders, Allergy, Other Disease Indications _x000D_

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores _x000D_

4) By Consumer Type: Pediatric, Adult, Geriatric_x000D_

_x000D_

Subsegments:_x000D_

1) By Anti-Psychotics: Atypical Anti-Psychotics, Typical Anti-Psychotics_x000D_

2) By Anti-Epileptics: Sodium Channel Blockers, GABA Analogs, Other Anti-Epileptics_x000D_

3) By Central Nervous System Stimulants: Amphetamine Derivatives, Methylphenidate, Other CNS Stimulants_x000D_

4) By Anxiolytics: Benzodiazepines, Non-Benzodiazepine Anxiolytics_x000D_

5) By Anti-Parkinsonian Drugs: Dopamine Agonists, MAO-B Inhibitors, Other Anti-Parkinsonian Drugs_x000D_

6) By Anti-Hypertensives: Beta-Blockers, Calcium Channel Blockers, ACE Inhibitors, Other Anti-Hypertensives_x000D_

7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Diclofenac, Other NSAIDs_x000D_

8) By Anti-Allergy Drugs: Antihistamines, Corticosteroids_x000D_

9) By Proton Pump Inhibitors: Omeprazole, Esomeprazole, Other PPIs_x000D_

10) By Other Drug Classes: Antiemetics, Antimigraine Drugs, Other Therapeutic Classes_x000D_

_x000D_

#Which Market Trends Are Expected To Define The Future Of The Orally Disintegrating Tablet Market?#_x000D_

Major firms in the orally disintegrating tablet market are driving innovation in drug formulation, particularly in the development of patient-centric drug delivery systems. This refers to a unique approach in which medicines are designed and provided in a manner that maximizes convenience and comfort for the patient, thereby enhancing treatment adherence and patient outcomes. For example, Viatris Inc., an American healthcare company, introduced Gen-Clozapine orally disintegrating tablets (ODT) onto the Canadian market in May 2025. The product, designed for patients with treatment-resistant schizophrenia, marked a significant advancement in managing the disease in the country, owing to its unique features. This was the first clozapine ODT introduced in Canada, which disintegrates rapidly in the mouth without the need for water, providing a friendly option for those struggling with swallowing or adherence issues. The tablets are available in various strengths (12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg), allowing for a flexible and individualized dosing approach. The implementation of clozapine, the only accepted antipsychotic for non-responsive schizophrenia, is supported by the ODT formulation aligning with well-established treatment standards._x000D_

_x000D_

#Who Are The Dominant Players In The Orally Disintegrating Tablet Market Today?#_x000D_

Major companies operating in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy’s Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions, KalVista Pharmaceuticals Inc. _x000D_

_x000D_

#Access The Complete Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/orally-disintegrating-tablet-global-market-report_x000D_

_x000D_

#Which Regional Markets Are Emerging As Key Hubs For The Orally Disintegrating Tablet Market?#_x000D_

North America was the largest region in the orally disintegrating tablet market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orally disintegrating tablet market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Customize Your Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=25857&type=smp_x000D_

_x000D_

Browse Through More Reports Similar to the Global Orally Disintegrating Tablet Market 2025, By The Business Research Company_x000D_

_x000D_

Dental Flap Surgery Global Market Report 2025_x000D_

https://www.thebusinessresearchcompany.com/report/dental-flap-surgery-global-market-report_x000D_

_x000D_

Intranasal Drug Delivery Devices Global Market Report 2025_x000D_

https://www.thebusinessresearchcompany.com/report/intranasal-drug-delivery-devices-global-market-report_x000D_

_x000D_

Surface Disinfectant Global Market Report 2025_x000D_

https://www.thebusinessresearchcompany.com/report/surface-disinfectant-global-market-report_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Orally Disintegrating Tablet Market Evolve in Terms of Growth and Size by 2029?

The market size for orally disintegrating tablets has been expanding robustly over recent years. The market is set to escalate from a value of $14.88 billion in 2024 to $16.20 billion in 2025, realizing a compound annual growth rate (CAGR) of 8.8%. Factors contributing to growth during the historic period include a surge in pediatric and geriatric populations, a rising incidence of central nervous system disorders, amplified demand for easy-to-use drug delivery methods, an increase in dysphagia cases, and a heightened utilization of outpatient care.

Anticipations are high for a significant expansion of the orally disintegrating tablet market in the coming years; it is projected to surge to a valuation of $22.53 billion in 2029, representing a compound annual growth rate (CAGR) of 8.6%. Factors contributing to this growth over the projected period include the escalating crisis of chronic diseases, a rise in self-medicated treatment, the growing influence of telemedicine and e-pharmacies, increasing emphasis on individualized treatment, mounting demand for vegan and allergen-friendly options, and a growing senior citizen demographic. Key trends throughout this anticipated period entail the creation of multi-drug orally disintegrating tablets, fusion with digital health platforms, enhancements in packaging for better stability and mobility, taste-alteration technologies, as well as ongoing progress in formulation technology.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25857&type=smp

What factors are expected to fuel Orally Disintegrating Tablet market growth in the coming years?

The growth of the orally disintegrating tablet market is expected to be driven by a growing prevalence of neurological disorders. These disorders affect the brain and peripheral nerves disrupting the normal operations of the nervous system. The increasing incidence of such disorders is primarily due to prolongation in human life span as disorders like Alzheimer’s and Parkinson’s begin to manifest more frequently with age. By facilitating easier and quicker drug administration, orally disintegrating tablets have proven beneficial for those with neurological conditions, especially those suffering from swallowing difficulties known as dysphagia, or cognitive impairments. They also enhance the effectiveness of therapy by encouraging proper medication adherence and ensuring appropriate timing of dosages. For instance, data from March 2023, as provided by the Alzheimer’s Association, an American voluntary health organization, shows that in 2023, around 6.7 million Americans aged 65 and above are living with Alzheimer’s dementia. The projection for 2060 stands at an escalated figure of 13.8 million. Such rising rates of neurological disorders are propelling the growth of the orally disintegrating tablet market.

What Are The Key Findings From The Segmentation Analysis Of The Orally Disintegrating Tablet Market?

The orally disintegrating tablet market covered in this report is segmented –

1) By Drug Class: Anti-Psychotics, Anti-Epileptics, Central Nervous System Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, Non-Steroidal Anti-Inflammatory Drugs, Anti-Allergy Drugs, Proton Pump Inhibitors, Other Drug Classes

2) By Disease Indication: Central Nervous System Disease, Gastrointestinal Disease, Cardiovascular System Disorders, Allergy, Other Disease Indications

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores

4) By Consumer Type: Pediatric, Adult, Geriatric

Subsegments:

1) By Anti-Psychotics: Atypical Anti-Psychotics, Typical Anti-Psychotics

2) By Anti-Epileptics: Sodium Channel Blockers, GABA Analogs, Other Anti-Epileptics

3) By Central Nervous System Stimulants: Amphetamine Derivatives, Methylphenidate, Other CNS Stimulants

4) By Anxiolytics: Benzodiazepines, Non-Benzodiazepine Anxiolytics

5) By Anti-Parkinsonian Drugs: Dopamine Agonists, MAO-B Inhibitors, Other Anti-Parkinsonian Drugs

6) By Anti-Hypertensives: Beta-Blockers, Calcium Channel Blockers, ACE Inhibitors, Other Anti-Hypertensives

7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Diclofenac, Other NSAIDs

8) By Anti-Allergy Drugs: Antihistamines, Corticosteroids

9) By Proton Pump Inhibitors: Omeprazole, Esomeprazole, Other PPIs

10) By Other Drug Classes: Antiemetics, Antimigraine Drugs, Other Therapeutic Classes

What Long-Term Trends Are Likely To Affect The Orally Disintegrating Tablet Market?

Leading businesses in the orally disintegrating tablet market are concentrating on innovative drug formulation, including patient-centered drug delivery systems, to boost treatment adherence and better patient outcomes. A patient-centered drug delivery system essentially involves the development and administration of medication that is simpler and more comfortable for patients, thus enhancing their treatment experience and compliance. For example, in May 2025, Viatris Inc., a healthcare firm based in the US, introduced Gen-Clozapine orally disintegrating tablets (ODT) to the Canadian market as a novel therapy for treatment-resistant schizophrenia. It brings several distinctive attributes, establishing it as a valuable addition to managing treatment-resistant schizophrenia in Canada. Being the first clozapine orally disintegrating tablet (ODT) in the country, it offers a patient-friendly solution that dissolves rapidly in the mouth without the need for water, proving helpful for those with trouble swallowing or issues with adherence. The product comes in various strengths (12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg), facilitating flexible and accurate dose adjustment based on the specific needs of each patient. Using clozapine, the sole approved antipsychotic for treatment-resistant schizophrenia, the ODT formulation helps conform to existing treatment guidelines.

What Are The Most Active Companies In The Orally Disintegrating Tablet Market Today?

Major companies operating in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy’s Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions, KalVista Pharmaceuticals Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/orally-disintegrating-tablet-global-market-report

Which Regional Markets Are Attracting The Most Investment In Orally Disintegrating Tablet?

North America was the largest region in the orally disintegrating tablet market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orally disintegrating tablet market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25857&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model